Cargando…
Ongoing Developments and Clinical Progress in Drug-Loaded Red Blood Cell Technologies
Engineered red blood cells (RBCs) appear to be a promising method for therapeutic drug and protein delivery. With a number of agents in clinical trials (e.g., dexamethasone 21-phosphate in ataxia telangiectasia, asparaginase in pancreatic cancer/acute lymphoblastic leukemia, thymidine phosphorylase...
Autores principales: | Rossi, Luigia, Pierigè, Francesca, Aliano, Mattia Paolo, Magnani, Mauro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7211199/ https://www.ncbi.nlm.nih.gov/pubmed/32198632 http://dx.doi.org/10.1007/s40259-020-00415-0 |
Ejemplares similares
-
Efficient Cocaine Degradation by Cocaine Esterase-Loaded Red Blood Cells
por: Rossi, Luigia, et al.
Publicado: (2020) -
Engineering new metabolic pathways in isolated cells for the degradation of guanidinoacetic acid and simultaneous production of creatine
por: Bianchi, Marzia, et al.
Publicado: (2022) -
Meeting the ongoing challenges of outcome selection in surgical oncology trials
por: Alkhaffaf, Bilal, et al.
Publicado: (2022) -
Macrophage Depletion by Free Bisphosphonates and Zoledronate-Loaded Red Blood Cells
por: Sabatino, Raffaella, et al.
Publicado: (2014) -
Emerging Technologies for Delivery of Biotherapeutics and Gene Therapy Across the Blood–Brain Barrier
por: Stanimirovic, Danica B., et al.
Publicado: (2018)